DHR Danaher Corporation

company

SEC Filings & Insider Trading Activity 2026

Risk Factors

• • IEEPA tariff authority struck down by U.S. Supreme Court Feb 2026; administration pursuing new tariffs under alternative authority — full impact still uncertain
• • ~59% of 2025 sales from outside U.S.; China alone ~11% of sales, with government-mandated volume-based procurement programs actively suppressing prices
• • Sole/limited-source suppliers for key components; supply interruptions cannot be quickly remedied due to regulatory qualification requirements
• • $18.4B outstanding debt as of Dec 31, 2025; additional debt expected to finance pending Masimo Corporation acquisition
• • FDA staffing reductions risk delays to 510(k) clearances and inspection schedules across Danaher's regulated medical device product lines

Business Overview

• • Global science/technology platform across Biotechnology, Life Sciences, and Diagnostics segments; high recurring-revenue model via consumables and direct sales in ~50 countries
• • ~60,000 employees (associates) as of Dec 31, 2025; ~22,000 in North America, ~20,000 Western Europe, ~15,000 high-growth markets
• • US geographic concentration notable: North America represents 41% of sales in the United States alone; high-growth markets (Eastern Europe, Middle East, Africa, Latin America, Asia ex-Japan/AU/NZ) flagged as key future growth driver
• • EU MDR/IVDR compliance deadlines extended to May 2026–Dec 2028 (MDR) and May 2026–May 2028 (IVDR), creating ongoing regulatory adaptation burden across Diagnostics and Life Sciences portfolios
• • Life Sciences segment anchors on 2023 Abcam acquisition (protein consumables/antibodies), the most recent portfolio addition, reinforcing proteomics and drug-discovery consumables as strategic build-out priority

Management Discussion & Analysis

• • Revenue $24.6B, up 3.0% YoY; core sales +2.0% driven by Biotechnology (+6.5% core) and Diagnostics (+1.5% core), offset by Life Sciences (-1.5% core)
• • Operating margin 19.1% vs 20.4%; gross margin 59.1% vs 59.5%; SG&A 33.5% vs 32.5% of sales, pressured by $533M impairment charges
• • Best segment: Biotechnology — sales $7.3B (+8.0%), operating margin 25.6% vs 24.9%; worst: Life Sciences — flat sales $7.3B, operating margin collapsed to 7.1% vs 12.0%
• • Operating cash flow $6.4B; capex $1.2B; share buybacks $3.1B; dividends $878M; net debt rose to ~$18.4B total debt vs $16.0B in 2024
• • 2026 outlook: Bioprocessing growth trend similar to 2025; Life Sciences modest improvement but below historical levels; Diagnostics higher growth as China headwinds ease; tariff costs <$300M in 2025 with ongoing uncertainty from trade policy shifts

What are the latest DHR SEC filings in 2026?

Danaher Corporation (DHR) has filed a 10-K annual report on February 24, 2026, a 10-Q quarterly report on April 21, 2026, an 8-K current report on August 3, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did DHR file its most recent 10-K annual report?

Danaher Corporation (DHR) filed its most recent 10-K annual report on February 24, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view DHR 10-Q quarterly reports?

Danaher Corporation (DHR)'s most recent 10-Q quarterly report was filed on April 21, 2026. SignalX displays every DHR 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has DHR filed recently?

Danaher Corporation (DHR)'s most recent 8-K was filed on August 3, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find DHR insider trading activity (Form 4)?

SignalX aggregates every DHR Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does DHR file with the SEC?

Danaher Corporation (DHR) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new DHR filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Danaher Corporation (DHR).

What is DHR's SEC CIK number?

Danaher Corporation (DHR)'s SEC CIK (Central Index Key) number is 313616. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 313616 to look up all DHR filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find DHR return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Danaher Corporation (DHR) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.